Bruno François

Bruno François

Auto-generated profile, based on publicly available information

Bruno François

Réanimation Polyvalente, Inserm CIC 1435 & UMR Inserm 1092, CHU Dupuytren, Limoges, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2002 in JAMA
Verified
Journal Article
Closed access
PDF file
DADjillali Annane
Djillali Annane
VSVéronique Sébille
Véronique Sébille
CCClaire Charpentier
Claire Charpentier
PBPierre-Edouard Bollaert
Pierre-Edouard Bollaert
BFBruno François
Bruno François
EBEric Bellissant
Eric Bellissant
Research from JAMA — Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock — ContextSeptic shock may be associated with relative adrenal insufficiency. Thus, a replacement therapy of low doses of corticosteroids has been proposed to treat septic shock.ObjectiveTo assess whether low doses of corticosteroids improve 28-day survival in patients with septic shock and relative adrenal insufficiency.Design and SettingPlacebo-controlled, randomized, double-blind, parallel-group trial performed in 19 intensive care units in France from October 9, 1995, to February 23, 1999.PatientsThree hundred adult patients who fulfilled usual criteria for septic shock were enrolled after undergoing a short corticotropin test.InterventionPatients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50-µg tablet once daily) (n = 151) or matching placebos (n = 149) for 7 days.Main Outcome MeasureTwenty-eight-day survival distribution in patients with relative adrenal insufficiency (nonresponders to the corticotropin test).ResultsOne patient from the corticosteroid group was excluded from analyses because of consent withdrawal. There were 229 nonresponders to the corticotropin test (placebo, 115; corticosteroids, 114) and 70 responders to the corticotropin test (placebo, 34; corticosteroids, 36). In nonresponders, there were 73 deaths (63%) in the placebo group and 60 deaths (53%) in the corticosteroid group (hazard ratio, 0.67; 95% confidence interval, 0.47-0.95; P = .02). Vasopressor therapy was withdrawn within 28 days in 46 patients (40%) in the placebo group and in 65 patients (57%) in the corticosteroid group (hazard ratio, 1.91; 95% confidence interval, 1.29-2.84; P = .001). There was no significant difference between groups in responders. Adverse events rates were similar in the 2 groups.ConclusionIn our trial, a 7-day treatment with low doses of hydrocortisone and fludrocortisone significantly reduced the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events.

1 May 2014 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
JVJean-Louis Vincent
Jean-Louis Vincent
JMJohn C Marshall
John C Marshall
SÑSilvio A. Ñamendys-Silva
Silvio A. Ñamendys-Silva
BFBruno François
Bruno François
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
YSYasser Sakr
Yasser Sakr

27 November 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
SLSimon Lambden
Simon Lambden
PLPierre Francois Laterre
Pierre Francois Laterre
MLMitchell M. Levy
Mitchell M. Levy
BFBruno Francois
Bruno Francois
The Sequential Organ Failure Assessment or SOFA score was developed to assess the acute morbidity of critical illness at a population level and has been widely validated as a tool for this purpose across a range of healthcare settings and environments.In recent years, the SOFA score has become extensively used in a range of other applications. A change in the SOFA score of 2 or more is now a defining characteristic of the sepsis syndrome, and the European Medicines Agency has accepted that a change in the SOFA score is an acceptable surrogate marker of efficacy in exploratory trials of novel therapeutic agents in sepsis. The requirement to detect modest serial changes in a patients’ SOFA score therefore means that increased clarity on how the score should be assessed in different circumstances is required.This review explores the development of the SOFA score, its applications and the challenges associated with measurement. In addition, it proposes guidance designed to facilitate the consistent and valid assessment of the score in multicentre sepsis trials involving novel therapeutic agents or interventions.ConclusionThe SOFA score is an increasingly important tool in defining both the clinical condition of the individual patient and the response to therapies in the context of clinical trials. Standardisation between different assessors in widespread centres is key to detecting response to treatment if the SOFA score is to be used as an outcome in sepsis clinical trials.

1 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
DAdjillali Annane
djillali Annane
ARAlain Renault
Alain Renault
CBChristian Brun-Buisson
Christian Brun-Buisson
Bruno MégarbaneBruno Mégarbane
Bruno Mégarbane
JQJean-Pierre Quenot
Jean-Pierre Quenot
EBEric Bellissant
Eric Bellissant
Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock.

20 March 2013 in JAMA
Verified
Journal Article
Open access
PDF file
SOSteven M. Opal
Steven M. Opal
PLPierre-Francois Laterre
Pierre-Francois Laterre
BFBruno Francois
Bruno Francois
SLSteven P. LaRosa
Steven P. LaRosa
DADerek C. Angus
Derek C. Angus
FGfor the ACCESS Study Group
for the ACCESS Study Group
Severe sepsis, a syndrome of acute infection complicated by organ dysfunction, is caused by a dysregulated systemic inflammatory response. Sepsis can progress to systemic hypotension (septic shock), manifest by hypoperfusion of vital organs, multiple organ dysfunction, and death.1-3

29 September 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EAEdward Abraham
Edward Abraham
PLPierre-François Laterre
Pierre-François Laterre
RGRekha Garg
Rekha Garg
HLHoward Levy
Howard Levy
DTDeepak Talwar
Deepak Talwar
WMWilliam L. Macias
William L. Macias
In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death.